Table 2.

Concentration–responses of aristolactam derivatives on cytotoxicity and anti-HIV activity.

Compound	IC50 (μmol/L)a	CC50 (μmol/L)b	SIc
1	0.69 ± 0.09	6.88 ± 0.31	9.94
2	1.03 ± 0.38	16.91 ± 3.22	16.45
3	3.73 ± 1.00	17.15 ± 0.34	4.59
4	3.07 ± 0.22	6.98 ± 0.09	2.27
5	1.07 ± 0.06	4.51 ± 0.96	4.23
6	1.06 ± 0.03	4.97 ± 0.62	4.70
7	2.00 ± 0.61	3.62 ± 0.15	1.80
8	0.55 ± 0.01	3.72 ± 0.01	6.74
9	0.44 ± 0.01	3.64 ± 0.08	8.31
Seliciclib	2.29 ± 0.40	25.49 ± 0.17	11.11

The inhibitory effects on HIV-1 infection and cell viability were determined in TZM-bl cells infected with HIV-1_NL4-3 at an MOI of 1.

^aIC₅₀: half-maximal inhibitory concentration.

^bCC₅₀: concentration that reduces cell viability by 50%.

^cSI: selectivity index, i.e. the ratio of IC₅₀ to CC_50.